Kadmon Investors and Media

Investors

Press Releases

Press Releases

Kadmon Announces Appointment of Dr. Simon Cooper as Chief Medical Officer

NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper , MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021 . In this role, Dr. Cooper will oversee the Company's medical and clinical activities... Read More

Kadmon to Present at Upcoming Investor Conferences

NEW YORK, NY / ACCESSWIRE / February 24, 2021 /   Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that Harlan W. Waksal , M.D., President and Chief Executive Officer, will present and host investor meetings at the following virtual investor conferences: Raymond James 42 nd Annual Institutional... Read More

Kadmon Announces Closing of $240 Million Convertible Senior Notes Offering Including Full Exercise of $40 Million Over-Allotment Option

NEW YORK, NY / ACCESSWIRE / February 16, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced the closing of $240 million aggregate principal amount of 3.625% convertible senior notes due 2027 (the "Notes") in a private, overnight offering to qualified institutional buyers pursuant to Rule... Read More

Kadmon Announces Pricing of $200 Million Convertible Senior Notes Offering with 100% Capped Call Transactions

NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced the pricing of $200 million aggregate principal amount of 3.625% convertible senior notes due 2027 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under... Read More

Kadmon Announces Proposed $150 Million Convertible Senior Notes Offering with Capped Call Transactions

NEW YORK, NY / ACCESSWIRE / February 10, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced its intent to offer, subject to market conditions and other factors, $150 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") in a private offering to qualified... Read More

Kadmon Announces Publication of Preclinical Data Demonstrating Anti-PD-L1/IL-15 Fusion Protein KD033 Achieves Robust Anti-Tumor Response

NEW YORK, NY / ACCESSWIRE / February 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of preclinical data demonstrating that KD033, the Company's anti-PD-L1/IL-15 fusion protein, achieved robust anti-tumor responses in multiple syngeneic tumor models.... Read More
Displaying 11 - 16 of 16